Panel Discussion: Accelerating Access to Liquid Biopsy Testing Through Kitted NGS Solutions
Time: 3:00 pm
day: Day One Track B PM
Details:
- Liquid biopsy testing is an important clinical tool to help guide therapeutic management of cancer patients and, to date, has largely been led by large, centralized testing reference laboratories (e.g., Guardant, Foundation Medicine)
- To maximize global access to this important testing and associated targeted therapies, local and regional laboratories are exploring kitted solutions to perform this testing on their in-house NGS platforms in a timely and cost-effective manner
- External clinical evaluations of Pillar Biosciences suite of kitted NGS assays, workflow, cost and data analysis software provide a compelling value proposition for laboratories looking to internalize LBx testing, and pharmaceutical organizations interested in expanding patient access around the world
